ZeinCRO, a CRO based in Europe, has reinforced its position in Central- and South- Eastern Europe (CSEE), with the opening of offices in 5 additional countries, extending its reach to 14 countries in total.

 In addition to its established presence in Cyprus, Greece, Hungary, Romania and Turkey, ZeinCRO now has offices in Bulgaria, Czech Republic, Estonia, FYROM and Poland. With an expanded workforce of more than 200 and over a decade’s operational experience, ZeinCRO is now positioned to offer its global drug development customers clinical trial services in 14 countries—including Latvia, Lithuania, Moldova and Slovakia—that cover the majority of the geographical regions of CSEE and provide access to a population of 250 million people.

 “Our extensive experience in providing specialist clinical services has taught us that, in order to gain a thorough understanding of a particular community and to forge long-lasting relationships with authorities and healthcare professionals, we need to establish local presence,” said Gregory Sivolapenko, chairman of ZeinCRO. “Our expansion in these additional countries underlines our efforts to set new standards for successful clinical trials and become the leading single provider of clinical research in the CSEE region.”

 ZeinCRO delivers bespoke clinical research services that are flexible and ethical, maximizing patient recruitment and compliance. In addition to clinical research services, ZeinCRO provides additional services in the areas of post-marketing safety and efficacy studies, regulatory affairs and pharmacovigilance including risk management plans.